Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A0001 phase 2a study in patients with the A3243G mitochondrial DNA point mutation
2009-014263-40Phase 2Terminated
- Sponsor
- Penwest Pharmaceuticals Co.
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mitochondriopathy comparing alpha-tocopherolquinone with placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Cardiac function assessments. Started Sep 2009; status: terminated.
02
Drugs
alpha-tocopherolquinone
03
Conditions
Mitochondriopathy
Beyond the preview
Go deeper on 2009-014263-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014263-40.